CN101418001B - Dipeptidase-IV inhibitor sulfonyl urea derivates - Google Patents

Dipeptidase-IV inhibitor sulfonyl urea derivates Download PDF

Info

Publication number
CN101418001B
CN101418001B CN200810166086XA CN200810166086A CN101418001B CN 101418001 B CN101418001 B CN 101418001B CN 200810166086X A CN200810166086X A CN 200810166086XA CN 200810166086 A CN200810166086 A CN 200810166086A CN 101418001 B CN101418001 B CN 101418001B
Authority
CN
China
Prior art keywords
compound
acceptable salt
pharmacy acceptable
hydrogen atom
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200810166086XA
Other languages
Chinese (zh)
Other versions
CN101418001A (en
Inventor
黄振华
赵红宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Ao He Research Institute Co Ltd
Original Assignee
Shandong Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xuanzhu Pharma Co Ltd filed Critical Shandong Xuanzhu Pharma Co Ltd
Priority to CN200810166086XA priority Critical patent/CN101418001B/en
Publication of CN101418001A publication Critical patent/CN101418001A/en
Application granted granted Critical
Publication of CN101418001B publication Critical patent/CN101418001B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention belongs to the technical field of medicine, and in particular relates to dipeptidyl peptidase IV inhibitor sulfonylurea derivatives of a general formula (I), pharmaceutically acceptable salts or isomers thereof, wherein R<1>, T<2>, R<3>, R<4>, R<5>, X and Y are as defined in the specification. The invention also relates to methods for preparing the compounds, pharmaceutical compositions containing the compounds, and application of the compounds to the preparation of drugs for the treatment and/or prevention of diabetes, non-insulin-dependent diabetes, hyperglycemia, and insulin resistance.

Description

The Dipeptidase-IV inhibitor sulfonyl urea derivates
1, technical field
The invention belongs to medical technical field, be specifically related to Dipeptidase-IV inhibitor sulfonyl urea derivates, its pharmacy acceptable salt or its isomer, the preparation method of these compounds, the pharmaceutical composition that contains these compounds, and these compounds treat and/or prevent application in the medicine of diabetes, non-insulin-dependent diabetes mellitus (NIDDM), hyperglycemia, insulin resistance in preparation.
2, background technology
Diabetes are a kind of whole body chronic metabolic disease that normal level causes that exceed owing to blood sugar is out of control.Substantially be divided into four classes, comprise: I type (insulin-dependent), II type (non-insulin-depending type), other type and gestational diabetes.I type and type ii diabetes belong to primary diabetes mellitus, are modal two kinds of forms, are caused by the h and E factor interaction.The cause of disease of diabetes is very complicated, but is because Regular Insulin is absolute or relative the shortage after all, or insulin resistant.Its characteristics are because the absolute or relative deficiency of Regular Insulin and target cell to the susceptibility reduction of Regular Insulin, cause the metabolism disorder of carbohydrate, protein, fat, ionogen and water.
In recent years, because the rhythm of life that the change of growth in the living standard, dietary structure, day are becoming tight and few moving mode of life of sitting etc. all multifactor more, whole world onset diabetes rate increases rapidly, and diabetes have become the chronic disease of the third-largest serious threat human health after tumour, cardiovascular pathological changes.Present global diabetic subject has surpassed 1.2 hundred million people, China patient people the second in the world of living in groups.According to statistics, the diabetic subject that made a definite diagnosis of China reaches more than 4,000 ten thousand, and with annual 1000000 speed increase.Wherein, the type i diabetes patient accounts for 10%, and the type ii diabetes patient accounts for 90%.Diabetes have become the public health problem of people's growing interests.
The type i diabetes medicine mainly is insulin preparation and surrogate thereof at present; For the treatment of type ii diabetes, main medicine is an oral antidiabetic drug, roughly is divided into sulfourea, biguanides, Chinese medicine preparation, other antidiabetic drugs and adjuvant drug.Though it has good curative effect, medicine can not kept long-term efficacy aspect the hyperglycemia reducing, can not be at the cause of disease and effective mitigate the disease.Many antidiabetic medicines at first can fine controlling blood sugar, but along with the continuity of medication treatment then can not keep curative effect, Here it is, and people adopt conjoint therapy or use one of principal element of other different classes of medicines instead, and existing antidiabetic medicine to lack permanently effective major cause is because their mechanism of action is to increase target tissue to the susceptibility of insulin action or improve the activity that pancreas produces Regular Insulin, but the decay basic cause of disease of these diabetes of pancreatic beta cell function is lacked targeting.
Dipeptidase-IV (DPP-IV) extensively exists in vivo; it is a kind of cell surface protein that relates to the various biological function; by suppressing the DPP-IV activity; protected the activity of GLP-1 and GIP etc.; promote insulin secretion; have the effect of protection β cell function in the time of lowering blood glucose, and can not cause side effects such as hypoglycemia and weight increase.
At present the inhibitor of first DPP-IV of listing is sitagliptin phosphate, and security preferably and tolerance are arranged, and finds also that at present the patient who uses has weight increase or potential to lose weight and symptom such as oedema.The structural formula of sitagliptin is as follows:
Figure G200810166086XD00021
Gliclazide is the oral sulfonylurea hypoglycemic agents of the s-generation, can reduce platelet adhesion reaction power, reduces the blood plasma specific viscosity, reduces ADP inductive platelet aggregation, improves the nail fold microcirculation.
Figure G200810166086XD00022
Gliclazide
Yet gliclazide has the serious delay hypoglycemia and the untoward reaction of hepatic renal dysfunction clinically, and the inhibitor medicaments activity of DPP-IV is relatively poor simultaneously, can not meet clinical needs, and is badly in need of the better anti-type ii diabetes medicine of exploitation and satisfies clinical application.
3, summary of the invention
In order to address the above problem, further improve and optimize the DPP-IV inhibitor, the inventor provides a class new DPP-IV inhibitor through great deal of experimental.
Technical scheme of the present invention is as follows:
The invention provides the compound shown in the general formula (I), its pharmacy acceptable salt or its isomer:
Wherein: R 1Represent following groups:
Figure G200810166086XD00024
R 2, R 3Independently represent hydrogen atom or C respectively 1-6Alkyl;
R 4, R 5Independently representative respectively:
(1) hydrogen atom,
(2) halogen atom,
(3) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkyl,
(4) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkoxyl group,
(5) cyano group, or
(6) hydroxyl;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently representative respectively:
(1) hydrogen atom,
(2) cyano group,
(3) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkyl, or
(4) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkoxyl group.
Preferred compound is:
Figure G200810166086XD00031
Wherein, R 1, R 2, R 3, R 4, R 5, X and Y be as above-mentioned definition.
Preferred again compound is:
Wherein: R 1Represent following groups:
Figure G200810166086XD00032
R 2, R 3Independently represent hydrogen atom respectively, methyl or ethyl;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, bromine atoms, methyl, methyl fluoride, difluoromethyl, trifluoromethyl, methoxyl group or cyano group;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently representative respectively:
(1) hydrogen atom, or
(2) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-4Alkyl.
Further preferred compound is:
Wherein: R 1Represent following groups:
Figure G200810166086XD00041
R 2, R 3Independently represent hydrogen atom or methyl respectively;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, methyl, trifluoromethyl or cyano group;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently represent hydrogen atom, methyl, ethyl or trifluoromethyl respectively.
" halogen atom " of the present invention is fluorine atom, chlorine atom, bromine atoms or iodine atom.
" C of the present invention 1-6Alkyl " be C 1-6The alkyl of straight or branched, as methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, isobutyl-, sec-butyl, the tertiary butyl, n-pentyl, isopentyl, neo-pentyl, 3-amyl group, n-hexyl, 4-methyl amyl, 3-methyl amyl, 2-methyl amyl, 1-methyl amyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethyl-butyl, 1,2-dimethyl propyl etc.
" C of the present invention 1-6Alkoxyl group " be methoxyl group; oxyethyl group; positive propoxy; isopropoxy; n-butoxy; isobutoxy, sec-butoxy, tert.-butoxy, n-pentyloxy, isopentyloxy, neopentyl oxygen, the 3-pentyloxy, positive hexyloxy, 4-methyl pentyloxy, 3-methyl pentyloxy, 2-methyl pentyloxy, 1-methyl pentyloxy, 3,3-dimethyl butoxy, 2,2-dimethyl butoxy, 1,1-dimethyl butoxy, 1,2-dimethyl butoxy, 1,3-dimethyl butoxy, 2,3-dimethyl butoxy, 2-ethyl butoxy, 1,2-dimethyl propoxy-, the ring propoxy-, cyclobutoxy group, 1-methyl cyclobutoxy group, cyclopentyloxy, cyclohexyloxy etc.
Further preferred compound is as follows:
Chemical name: 7 (R)-N-[3-amino-4-[4-(N-butylamine formyl radical) sulfamic-2,5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7,8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine is called for short compd A, and structural formula is as follows:
Chemical name: 7 (R)-N-[3-amino-4-[4-[N-(cyclopentyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2, the 5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7; 8-tetrahydrochysene-[1,2,4]-triazolo [4; 3-a] pyrazine, be called for short compd B, structural formula is as follows:
Figure G200810166086XD00051
Chemical name: 7 (R)-N-[3-amino-4-[4-[N-(cyclohexyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2, the 5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7; 8-tetrahydrochysene-[1,2,4]-triazolo [4; 3-a] pyrazine, be called for short Compound C, structural formula is as follows:
Figure G200810166086XD00052
The present invention also provides the preparation method of above-claimed cpd, and reaction equation is as follows, but is not limited only to following method:
Reactions steps:
Figure G200810166086XD00061
Raw material 1 compound 1
Figure G200810166086XD00062
Compound 2 compounds 3 compounds 4
Compound 5 compounds 6
Figure G200810166086XD00064
Compound 7 compounds 8
The preparation of step 1 compound 1
Raw material 1 is dissolved in the tetrahydrofuran (THF), drips n-Butyl Lithium/hexane solution, insulated and stirred then, drip the tetrahydrofuran (THF) cold soln of raw material 2 then, stirring reaction adds the shrend reaction of going out, reaction solution concentrates, and residuum adds ethyl acetate and hydrochloric acid, divides water-yielding stratum, use ethyl acetate extraction, merge organic layer, salt is washed, anhydrous magnesium sulfate drying, concentrating under reduced pressure, silicagel column purifying (eluent is the mixed solution of ethyl acetate and hexanaphthene) gets compound 1.
The preparation of step 2 compound 2
Compound 1 is dissolved in the acetonitrile, dripping hydrochloric acid then, the reaction solution stirring at room adds methyl alcohol, be concentrated into dried, operation triplicate, and then repeat once with toluene, solid, this solid slowly adds triethylamine with methylene dichloride dissolving back, and then slowly is added dropwise to (Boc) 2O, the reaction solution stirring at room, the solid that the filtering reaction generates, filtrate is diluted with methylene dichloride, respectively with HCl solution and saturated brine washing, anhydrous magnesium sulfate drying, silicagel column purifying, eluent are the mixed solution of acetonitrile and sherwood oil, get compound 2.
The preparation of step 3 compound 3
Add tetrahydrofuran (THF) in compound 2, ice bath cools off, and is added dropwise to the aqueous solution of lithium hydroxide then, the reaction solution stirring at room, concentrating under reduced pressure, residuum acetic acid ethyl dissolution, the washing of saturated sodium bicarbonate and salt solution, anhydrous magnesium sulfate drying, steam desolventize compound 3.
The preparation of step 4 compound 4
Add compound 3, ether, add triethylamine and isopropyl chlorocarbonate (ClCOO then iPr), finish, stirring reaction adds the ethyl acetate solution that contains diazomethane then, adds an amount of 1-methyl-3-nitro-1-nitrosoguanidine down in 0 ℃ and is dissolved in ether and 40% sodium hydroxide mixing solutions, 0 ℃ of following stirring reaction of reaction solution, the organic layer drying, mixed solution dilutes with ethyl acetate, saturated sodium bicarbonate and salt water washing, anhydrous magnesium sulfate drying is evaporated to dried compound 4.
The preparation of step 5 compound 5
Compound 4 is dissolved in the methyl alcohol, cooling adds diisopropyl ethyl amine and silver benzoate, reaction solution rises to stirring at room, reaction is finished, remove methyl alcohol under reduced pressure, residuum dissolves with methylene dichloride, filtering insoluble solid thing, and filtrate concentrates, the silicagel column purifying obtains solid, this solid is dissolved in the tetrahydrofuran (THF), adds then and contain in the water of lithium hydroxide the reaction solution stirring at room, dilute with ethyl acetate behind the concentration of reaction solution, anhydrous magnesium sulfate drying use in the washing of saturated sodium bicarbonate and salt, concentrated compound 5.
The preparation of step 6 compound 6
Under room temperature, throw compound 5, HOBT (1-hydroxy benzo triazole), DMF, add DCC (dicyclohexylcarbodiimide) then, the stirring at room reaction is crossed and is filtered out the solid that reaction generates, filtrate continuation adds in the reaction flask, add raw material 3, heat up and stir, reaction is finished, add entry, separate out solid,, get compound 6 with methyl alcohol and ethyl acetate mixed solution recrystallization.
The preparation of step 7 compound 7
Add methylene dichloride in the exsiccant reaction flask, compound 6 reduces temperature after the stirring and dissolving, slowly drip the dichloromethane solution of chloromethane sulphonyl under the vigorous stirring, drip and finish the intensification stirring reaction, reaction is finished, add dried feed 4 under the vigorous stirring, stirring reaction adds entry, saturated sodium-chloride washing respectively, anhydrous magnesium sulfate drying, remove solvent under reduced pressure, the residuum recrystallizing methanol gets compound 7.
The preparation of step 8 compound 8
In reaction flask, add compound 7, after the methylene dichloride dissolving, reduce temperature.Slowly drip raw material 5, elevated temperature, stirring reaction, be warming up to backflow again, be added dropwise to hydrochloric acid under the vigorous stirring, after the reaction, reduce to room temperature, tell organic layer, water layer is transferred pH to 9 with sig water under ice bath, separate out solid filtering, successively water, ethyl acetate washing, get crude product, get compound 8 with ethyl alcohol recrystallization.
R in the above reaction equation 1, R 2, R 3, R 4, R 5, X and Y representative group as mentioned before.
The above-mentioned arbitrary compound pharmacy acceptable salt of the present invention comprises organic acid salt, inorganic acid salt, organic alkali salt, inorganic base salts.Organic acid comprises acetate, Phenylsulfonic acid, phenylformic acid, tosic acid, butene dioic acid, (2R, 3R)-2,3-dyhydrobutanedioic acid, camphorsulfonic acid, citric acid, ethyl sulfonic acid, fumaric acid, glyconic acid, L-glutamic acid, isethionic acid, lactic acid, toxilic acid, oxysuccinic acid, amygdalic acid, methylsulfonic acid, glactaric acid, nitric acid, pamoic acid, pantothenic acid, succsinic acid, tartrate etc., preferred Phenylsulfonic acid, tosic acid, butene dioic acid, citric acid, toxilic acid, fumaric acid, tartrate.Mineral acid comprises Hydrogen bromide, spirit of salt, nitric acid, sulfuric acid, phosphoric acid etc., preferred Hydrogen bromide, spirit of salt, sulfuric acid, phosphoric acid.Organic bases comprises primary, the second month in a season and tertiary amine, be substituted amine and comprise naturally occurring replacement amine, cyclammonium and basic ion exchange resin, preferred arginine, trimethyl-glycine, caffeine, choline, N, N '-dibenzyl-ethylenediamin, diethylamine, 2-diethylin ethanol, the 2-dimethylaminoethanol, thanomin, quadrol, N-ethyl-morpholine, N-ethylpiperidine, meglumine, glucosamine, Histidine, Hai Baming, isopropylamine, Methionin, methylglucosamine, morpholine, piperazine, piperidines, the polyamides resin, PROCAINE HCL, PHARMA GRADE, purine, Theobromine, triethylamine, Trimethylamine 99, tripropyl amine, Trometamol etc.Mineral alkali comprises the basic cpd of ammonium and lithium, sodium, potassium, calcium, magnesium, zinc, barium, aluminium, iron, ketone, ferrous, manganese, bivalent manganese etc., the basic cpd of preferred ammonium and lithium, sodium, potassium, calcium, magnesium, zinc, barium.
The compounds of this invention contains one or more asymmetric centers, thereby can be used as racemic modification and racemic mixture, single enantiomer, non-enantiomer mixture and single diastereomer.The compounds of this invention has asymmetric center, and each will independently produce two optical isomers this class asymmetric center, and scope of the present invention comprises all possible optical isomer and non-optical isomer mixture and pure or partial-purified compound.The present invention includes all isomeric forms of these compounds.Part of compounds of the present invention can exist with tautomeric forms, and it has the tie point of different hydrogen by one or more double-bond shifts.For example, ketone and its enol form are the keto-enol tautomerism bodies.Each tautomer and composition thereof all is included in the compound of the present invention.
Compound of the present invention can be united with one or more other medicines, and is more safer or more effective than single medicine.Can be with these other medicines and formula (I) compound simultaneously or in succession by a kind of approach and with its usual amounts administration.During administration simultaneously, be preferably the medicinal compositions of the unit dosage form that contains described other medicines and formula (I) compound.Can with formula (I) compound drug combination or respectively administration or in same medicinal compositions other activeconstituents of administration include, but are not limited to:
(a) other pepx IV inhibitor;
(b) insulin sensitisers comprises: (i) PPAR gamma agonist, as glitazones (for example troglitazone, pioglitazone, englitazone, MCC-555, Rosiglitazone etc.) and other PPAR part, comprise PPAR α/γ economic benefits and social benefits agonist, as KRP-297, with PPAR alfa agonists such as Fenofibric Acid derivative (gemfibrozil, clofibrate, fenofibrate and bezafibrate), (ii) biguanides, for example N1,N1-Dimethylbiguanide and phenformin and (iii) albumen network propylhomoserin phosphoesterase-1B (PTP-1B) inhibitor;
(c) Regular Insulin or insulin-mimickers;
(d) sulfonylurea and other Regular Insulin succagoga, for example tolbutamide and Glipizide, meglitinide and related drugs;
(e) alpha-glucosidase inhibitor (for example acarbose);
(f) glucagon receptor antagonist;
(g) GLP-1, GLP-1 stand-in and GLP-1 receptor stimulant;
(h) GLP and GLP stand-in and GLP receptor stimulant;
(i) PACAP, PACAP stand-in and PACAP acceptor 3 agonists;
(j) cholesterol reducing agent, (i) HMG-CoA reductase inhibitor (lovastatin for example, Simvastatin, Pravastatin, fluvastatin, Ah appropriate cuts down his spit of fland, rivastatin, itavastatin, superstatin and other statins), (ii) inner complex (Colestyramine, the dialkyl aminoalkyl derivative of colestipol and crosslinked dextran), (iii) nicotinic alcohol, nicotinic acid or other salt, (iv) PPAR alfa agonists, Fenofibric Acid derivative (gemfibrozil for example, clofibrate, fenofibrate and bezafibrate), (v) PPAR α/γ economic benefits and social benefits agonist, for example KRP-297; (vi) cholesterol absorption inhibitor, for example β-Gu Zaichun and ezetimibe, (vii) ethanoyl CoA, chole-sterol acyltransferase inhibitor, for example avasimibe and (viii) antioxidant, for example probucol;
(k) PPAR delta agonists;
(1) anti-obesity compound, for example Phenfluoramine, dexfenfluramine, phentermine, sibutramine, orlistat, neuropeptide Y 5 inhibitor and beta 3 adrenoreceptor agonists;
(m) ileal bile acid transfer protein inhibitor; With
(n) be used for the medicine of inflammation, for example acetylsalicylic acid, non-steroidal anti-inflammatory drug, glucocorticosteroid, sulphur nitrogen sulphur pyridine and epoxidase 2 are selected inhibitor.
Above-mentioned unite comprise compound of the present invention not only with a kind of other active compound and also with the associating of two or more other active compounds.Non-limiting example comprises that the have formula compound of (I) and two or more are selected from the associating of the active compound of biguanides, sulfonylurea, HMG-CoA reductase inhibitor, PPAR agonist, PTP-1B inhibitor, other DPP-IV inhibitor and anti-obesity compound.
The weight ratio of The compounds of this invention and second kind of activeconstituents can change, and it depends on the effective dose of various compositions.In general, with the effective dose that adopts separately.Therefore for example when compound of the present invention and other medicines drug combination, the weight ratio of The compounds of this invention and other medicines generally arrives between about 1:200 at about 200:1, is preferably about 20:1 and arrives between about 1:20.The drug combination of The compounds of this invention and other activeconstituents generally also can be in above-mentioned scope, but under each situation, should use the effective dose of each activeconstituents.
The present invention is claimed arbitrary compound recited above, its pharmacy acceptable salt or its isomer of comprising further; pharmaceutical composition with one or more pharmaceutical carriers and/or thinner; for clinically or pharmaceutically acceptable arbitrary formulation, be preferably oral preparations or injection.Wherein contain the compound 10mg～10g shown in the general formula (I) of physiology significant quantity, be preferably 25mg～5g, can be described activeconstituentss such as 25mg, 50mg, 75mg, 0.1g, 0.125g, 0.2g, 0.25g, 0.5g, 0.75g, 0.8g, 1g, 1.25g, 1.5g, 2g, 2.5g, 3g, 4g, 5g.Can be by 1～4 time arrangement every day, give described compound 1～2 time preferred every day.
The arbitrary compound of the present invention, its pharmacy acceptable salt or its isomer, can be oral or mode such as administered parenterally be applied to the patient who needs this treatment.
When being used for administered parenterally, can be made into injection.Injection means the intravital solution of confession injection, emulsion or the suspension that medicine is made and supplies to face with preceding preparation or be diluted to solution or the sterile preparation of the powder of suspension or strong solution that injection can be divided into injection liquid, injectable sterile powder and concentrated solution for injection.Injection liquid means that the confession that medicine is made is injected into sterile solution type injection liquid, emulsion-type injection liquid or the suspension type injection liquid of using in the body, can be used for intramuscularly, intravenous injection, intravenous drip etc.; Its specification has 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., and wherein large volume (generally the being not less than 100ml) injection liquid of using for intravenous drip also claims intravenous infusion.Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension, available suitable solvent for injection preparation back injection, also available intravenous infusion preparation posterior vein instils; Sterilized powder makes with solvent crystallization, spray-drying process or freeze-drying etc.Concentrated solution for injection means that confession that medicine is made faces the aseptic strong solution of using for intravenous drip with preceding dilution.
When making injection, can adopt the ordinary method production in the existing pharmacy field, optional use solvent or non-aqueous solvent.The most frequently used aqueous solvent is a water for injection, also available 0.9% sodium chloride solution or other suitable aqueous solution; Non-aqueous solvent commonly used is a vegetables oil, is mainly the injection soybean oil, and other also have the aqueous solution of ethanol, propylene glycol, polyoxyethylene glycol etc.During the preparation injection, can not add additives, also can add suitable additives, as osmotic pressure regulator, pH value conditioning agent, solubilizing agent, weighting agent, oxidation inhibitor, fungistat, emulsifying agent, suspending agent etc. according to the character of medicine.Osmotic pressure regulator commonly used comprises sodium-chlor, glucose, Repone K, magnesium chloride, calcium chloride, sorbyl alcohol etc., preferred sodium-chlor or glucose; PH value conditioning agent commonly used comprises acetic acid-sodium-acetate, lactic acid, Citric Acid-Sodium Citrate, sodium bicarbonate-yellow soda ash etc.; Solubilizing agent commonly used comprises Polysorbate 80, propylene glycol, Yelkin TTS, polyoxyethylenated castor oil etc.; Weighting agent commonly used comprises lactose, N.F,USP MANNITOL, sorbyl alcohol, dextran etc.; Oxidation inhibitor commonly used has S-WAT, sodium bisulfite, Sodium Pyrosulfite etc.; Fungistat commonly used is phenol, cresols, trichloro-butyl alcohol etc.Injection container commonly used has glass ampoule, vial, plastic ampoule, Plastic Bottle etc.
Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, pill, granule etc.; Also can be made into oral liquid, as oral solution, oral suspensions, syrup etc.Tablet means disk shape or the special-shaped flaky solid preparation that medicine and the auxiliary materials and mixing compacting that suits form, based on oral ordinary tablet, other has lozenge, Sublingual tablet, mouth paster, chewable tablet, dispersible tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet and enteric coated tablet etc.Capsule means medicine or is added with the auxiliary material filling in Capsules or be sealed in solid preparation in the soft capsule material, according to its dissolving and release characteristics, can be divided into hard capsule (being commonly referred to as capsule), soft capsule (capsule and pill), slow releasing capsule, controlled release capsule and enteric coated capsule etc.Pill means medicine and suitable auxiliary material uniform mixing, and the spherical or near-spherical solid preparation so that proper method is made comprises dripping pill, sugar-pill, piller etc.Granule means that medicine and suitable auxiliary material make the dried particles shape preparation with certain particle size, can be divided into soluble particles (being commonly referred to as particle), mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules and controlled release granule etc.Oral solution means that medicine dissolution makes for oral clarified liq preparation in suitable solvent.Oral suspensions means the insoluble solid pharmaceutical, is dispersed in the liquid medium, makes for oral suspension body preparation, also comprises dry suspensoid or dense suspension.Syrup means the dense aqueous sucrose solution that contains medicine.
When making oral preparations, can add suitable weighting agent, tackiness agent, disintegrating agent, lubricant etc.Weighting agent commonly used comprises starch, Icing Sugar, calcium phosphate, calcium sulfate two water things, dextrin, Microcrystalline Cellulose, lactose, pregelatinized Starch, N.F,USP MANNITOL etc.; Typical binders comprises Xylo-Mucine, PVP-K30, hydroxypropylcellulose, starch slurry, methylcellulose gum, ethyl cellulose, hypromellose, gelling starch etc.; Disintegrating agent commonly used comprises dry starch, polyvinylpolypyrrolidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose etc.; Conventional lubricants comprises Magnesium Stearate, talcum powder, sodium lauryl sulphate, micropowder silica gel etc.
Dipeptidase-IV (DPP-IV) is a kind of cell surface protein that relates to the various biological function.It has tissue distribution (intestines, kidney, liver, pancreas, placenta, thymus gland, spleen, epithelial cell, blood vessel endothelium, lymph and myelocyte, serum) and tissue and cell type expression level widely clearly.DPP-IV is confirmed as T type cell-stimulating mark CD26, and it can be at immunoregulatory in a large number, the endocrine and neurologic peptide of external cracking.This shows that there is the effect of diving in this peptase in the various diseases process of human body or other animal.
Pharmacological evaluation proves that the DPP-IV inhibitor can significantly suppress the DPP-IV activity, and protection GLP-1 activity promotes insulin secretion, reduces hyperglycemic-glycogenolytic factor after the meal, and lowering blood glucose improves anti-sugar amount; And have the active effect of protection GIP, can improve the concentration of GIP, strengthen the effect of its insulin secretion accelerating; The DPP-IV inhibitor can also improve glycolipid metabolism, prevents weight increase.
The present invention also provides new DPP-IV inhibitor to be used for the treatment of and/or to prevent purposes in the medicine of following disease in preparation.
Type ii diabetes and relative disease, now full confirmation GLP-1 and GIP can be by DPP-IV quick inactivatings in vivo, therefore DPP-IV inhibitor of the present invention can be used for treating a large amount of illnesss that type ii diabetes and treatment and prevention are followed type ii diabetes, comprises metabolic syndrome X, reactive hypoglycemia and glycosuria sexual abnormality lipidemia.Following disease, illness is relevant with type ii diabetes with symptom, therefore can treat by the methods of treatment that adopts The compounds of this invention, control or prevention in some cases: (1) hyperglycemia, (2) low dextrose tolerance, (3) insulin resistance, (4) obesity, (5) matter fat disease, (6) unusual lipidemia, (7) hyperlipidaemia, (8) hypertriglyceridemia, (9) hypercholesterolemia, (10) low HDL levels, (11) high HDL level, (12) atherosclerosis and sequela thereof, (13) vascular restenosis, (14) irritable bowel syndrome, (15) enteritis comprises crohnShi disease and ulcerative colitis, (16) retinopathy, (21) ephrosis, (22) neuropathy, (23) X syndromes, the hyperandrogenism (polycystic ovary syndrome) of (24) ovary and the disease of other tool insulin resistance; And the growth hormone deficiency disease, damage of intestines, immunosuppressive action, HIV infects, hemopoietic, neuronal disease, brain tumor is invaded and is shifted benign prostatauxe, seminal fluid motility, oulitis, osteoporosis etc.
Dipeptidase-IV inhibitor sulfonyl urea derivates of the present invention compared with prior art has the following advantages:
(1) Dipeptidase-IV inhibitor sulfonyl urea derivates of the present invention can suppress the activity of DPP-IV preferably, makes the interior GLP-1 level of body more stable;
(2) Dipeptidase-IV inhibitor sulfonyl urea derivates of the present invention has good security and tolerance in vivo, and incidence rate of adverse reaction reduces more;
(3) The compounds of this invention preparation technology is simple, and medicine purity height, yield height, steady quality are easy to carry out large-scale commercial production.
Below further set forth the beneficial effect of Dipeptidase-IV inhibitor sulfonyl urea derivates of the present invention, but this should be interpreted as that Dipeptidase-IV inhibitor sulfonyl urea derivates of the present invention only has following beneficial effect by external pharmacological evaluation.
The external pharmacologically active of experimental example 1 The compounds of this invention
Trial-product: compd A～C, the self-control, its chemical name, structural formula as mentioned before, the preparation method sees the preparation embodiment of each compound;
Reference substance: sitagliptin phosphate, commercial;
Experimental technique: accurately take by weighing trial-product and reference substance sitagliptin phosphate, add the DMSO dissolving, fully mixing is made into 100mM.Then with DMSO with above-mentioned mother liquor stepwise dilution to 10mM, 1mM, 100 μ M, 10 μ M.Get above-mentioned solution 4 μ l, add the damping fluid of 396 μ l, fully mixing is made into 100 μ M, 10 μ M, 1 μ M, 100nM.
1, fluorescent method detects the restraining effect to DPP-IV:
Get 5 μ l normal mouse serum, add the testing compound and the 24 μ l MgCl of 1 μ l different concns 2Damping fluid, preincubate 5 minutes in the room temperature behind the mixing, add 10 μ l100 μ M reaction substrates and 20 μ l damping fluids then, carry out fluorometric assay (excitation wave 380nm/ transmitted wave 460nm) behind the lucifuge mixing, measured 1 time every 3 minutes, add 25% acetate, 40 μ l termination reactions in the time of the 20th minute, the room temperature lucifuge was placed after 5 minutes, carried out fluorometric assay once more.
2, the fluorescent method detection compound is to the restraining effect of DPP-7:
Damping fluid (pH ≈ 5.5) with the cacodylate of the BSA of 0.1mg/ml and 100mM is a reaction solution, and the Nle-Pro-AMC of 5 μ M is that substrate and 1 μ l compound are 15 minutes (exciting light and wavelength of transmitted light are respectively 360nm and 460nm) of 37 ℃ of reactions.
3, the fluorescent method detection compound is to the restraining effect of DPP-8:
With the BSA of 0.1mg/ml and the sodium phosphate buffer of 50mM (pH ≈ 8.0) is reaction solution, and the Ala-Pro-7-amino-4-trifluormethylcoumarin of 100 μ M is that substrate and 1 μ l compound react 15 minutes (exciting light and wavelength of transmitted light are respectively 400nm and 505nm) at 37 ℃.
4, the fluorescent method detection compound is to the restraining effect of DPP-9:
With the BSA of 0.1mg/ml and the Tris/HCl damping fluid of 100mM (pH ≈ 7.4) is reaction solution, and the Gly-Pro-AMC of 100 μ M is that substrate and 1 μ l compound react 30 minutes (exciting light and wavelength of transmitted light are respectively 360nm and 460nm) at 37 ℃.
Experimental result and conclusion:
Table 1 The compounds of this invention is to activity and the selectivity of DPP-IV
Figure G200810166086XD00131
By table 1 as seen, compare with sitagliptin phosphate, The compounds of this invention A is slightly poor than sitagliptin phosphate to the activity of DPP-IV, and The compounds of this invention A is slightly poor than sitagliptin phosphate to the selectivity of DPP-7, and is suitable to selectivity and the sitagliptin phosphate of DPP-8, DPP-9; The compounds of this invention B, C omit than sitagliptin phosphate the activity of DPP-IV, and be suitable to selectivity and the sitagliptin phosphate of DPP-7, DPP-8, DPP-9, and therefore, compd B, Compound C be safety but also effective not only.
Pharmacologically active in the body of experimental example 2 The compounds of this invention
Trial-product: compd A～C, the self-control, its chemical name, structural formula structural formula as mentioned before, the preparation method sees the preparation embodiment of each compound;
Reference substance: gliclazide, commercial;
Experimental technique:
1, modeling: choose 90 of the rats of 200g left and right sides body weight, random packet, one group of normal control group (10) gives normal diet (fatty 12%, carbohydrate 60%, protein 28%); All the other 80 give high lipid food (fatty 41%, carbohydrate 41%, protein 18%), after raising for 2 weeks, the animal fasting be can't help water and is spent the night, and presses 60mg/kg body weight abdominal injection STZ, survey animal fasting plasma glucose (fasting blood glucose after 72 hours, FBG), be stabilized in the above person of 13.5mmol/L and be modeling success, 46 of film forming.The normal control group is with isodose Trisodium Citrate-citrate buffer solution tail vein injection.
2, experiment grouping and medication: become the mould rat to be divided into 5 groups at random by body weight and glucose level with 46, compd A medication group (is called for short 1 group of compound, 9), compd B medication group (is called for short 2 groups of compounds, 9), Compound C medication group (is called for short 3 groups of compounds, 9), gliclazide medication group (is called for short the gliclazide group, 9), pathology control group (be called for short pathologic group, 10).
Grouping of table 2 animal and administration
Figure G200810166086XD00141
6 groups of rats are irritated stomach treatment 1 time every day, all do not limit feed and drinking-water, and treatment cycle was 8 weeks.
Rat is surveyed fasting plasma glucose (FBG) level respectively at administration fasting at the 8th weekend 12 hours from tail vein blood.
3, fasting plasma glucose (FBG) level determination: (CA USA) goes up mensuration for LifeScan, Milpitas in blood glucose meter to get tail vein.
4, statistical study: all numerical value all are expressed as mean scholar standard deviation (mean ± s).Each measurement data all adopts SPSS11.0FOR WINDOWS software that data are carried out statistical treatment, a plurality of sample averages of single factor relatively use variance analysis, the multiple sample mean relatively adopts the q check in twos, before and after each group relatively with the t check of paired data.P＜0.05 o'clock is illustrated in statistics and goes up meaningful.
5, result: as shown in table 3, pathologic group and treatment group fasting plasma glucose are all apparently higher than normal group (P＜0.01); Treatment group fasting blood glucose level significantly is lower than pathologic group (P＜0.01); Fasting blood glucose level does not have significant difference (P〉0.05) between each treatment group, compd B, Compound C curer's glucose level is significantly less than the gliclazide group, prompting compd B, Compound C can obviously reduce type ii diabetes rat blood sugar level, improve the type ii diabetes carbohydrate metabolism disturbance.
Table 3 is respectively organized relatively (mean ± s) of rat FBG level
Figure G200810166086XD00142
Compare with normal group, *P＜0.01; Compare Δ P＜0.01 with pathologic group;
Conclusion: know that by table 1,3 The compounds of this invention B, Compound C are better than sitagliptin phosphate and gliclazide to the effect of type ii diabetes, integrate the advantage of two kinds of medicines, are applicable to the clinical development of anti-type ii diabetes.
4, embodiment
The embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following examples.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The auxiliary material of each formulation can be replaced with acceptable accessories in following examples, perhaps reduces, increases.
Embodiment 1 (2R, 5S)-2,5-dihydro-3,6-dimethoxy-2-[(2,5-difluorophenyl) methyl]-preparation of 5-isopropylpyrazine
With 9.2g (50mmol) (2S)-(+)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine is dissolved in the 300ml tetrahydrofuran (THF), then in-78 ℃, be added dropwise to 24ml (60mmol in the 30min, 2.5N) n-Butyl Lithium/hexane solution, insulated and stirred 30min is added dropwise to 2 of 8.9g (55mmol) then, the 50ml tetrahydrofuran (THF) cold soln of 5-two fluorine-based benzyl chlorides,-78 ℃ of stirring reaction 5h ,-78 ℃ add down the 100ml shrend reaction of going out, and reaction solution is concentrated, residuum adds ethyl acetate and 1N hydrochloric acid, divide water-yielding stratum, use ethyl acetate extraction three times, merge organic layer, salt is washed, anhydrous magnesium sulfate drying, concentrating under reduced pressure, silicagel column purifying (eluent is the mixed solution of ethyl acetate and hexanaphthene), get 10.8g solid target compound, yield: 69.4%.
The preparation of embodiment 2 (R)-2-(tertbutyloxycarbonyl) amido-3-(2, the 5-difluorophenyl) methyl propionate
With 15.5g (50mmol) (2R, 5S)-2,5-dihydro-3,6-dimethoxy-2-[(2,5-difluorophenyl) methyl]-the 5-isopropylpyrazine is dissolved in the 100ml acetonitrile, drips the hydrochloric acid of 100ml (1N) then, reaction solution stirring at room 24h, add methyl alcohol, be concentrated into driedly, this operates triplicate, and then repeat once with toluene, get solid, this solid dissolves the slowly triethylamine of adding 50g of back with the 400ml methylene dichloride, and then slowly is added dropwise to 24g (110mmol) (Boc) 2O, reaction solution stirring at room 8h, the solid that the filtering reaction generates, filtrate is diluted with methylene dichloride, and HCl solution and the saturated brine with 1N washs anhydrous magnesium sulfate drying respectively, the silicagel column purifying, eluent is the mixed solution of acetonitrile and sherwood oil, obtains 10.2g solid target compound, yield: 64.5%.
The preparation of embodiment 3 (R)-2-(tertbutyloxycarbonyl) amido-3-(2, the 5-difluorophenyl) propionic acid
(R)-2-(tertbutyloxycarbonyl) amido-3-(2 with 9.5g (30mmol), the 5-difluorophenyl) adds the 200ml tetrahydrofuran (THF) in the methyl propionate, ice bath cools off, and is added dropwise to the 200ml aqueous solution of 2.15g (90mmol) lithium hydroxide then, reaction solution stirring at room 15h, concentrating under reduced pressure, the residuum acetic acid ethyl dissolution, saturated sodium bicarbonate and salt solution washing, anhydrous magnesium sulfate drying, steaming desolventize the 6.9g solid, yield: 76.2%.
Embodiment 4 (R)-3-[(tertbutyloxycarbonyl) amido]-preparation of 1-diazonium-4-(2, the 5-difluorophenyl) butyl-2-ketone
(R)-2-(tertbutyloxycarbonyl) amido-3-(2 that adds 7.5g (25mmol), the 5-difluorophenyl) propionic acid, the 150ml ether, then in-30 ℃ of triethylamine and 4ml isopropyl chlorocarbonates that add 3g (30mmol) down, finish,-30 ℃ of stirring reaction 30min, add the ethyl acetate solution that contains the 5.3g diazomethane then, add an amount of 1-methyl-3-nitro-1-nitrosoguanidine down in 0 ℃ and be dissolved in ether and 40% sodium hydroxide mixing solutions, 0 ℃ of following stirring reaction 20min of reaction solution, the organic layer drying, mixed solution dilutes with ethyl acetate, saturated sodium bicarbonate and salt water washing, anhydrous magnesium sulfate drying, be evaporated to dried 7.0g solid target compound, yield: 85.8%.
Embodiment 5 (R)-3-[(tertbutyloxycarbonyl) amido]-the butyro-preparation of 4-(2, the 5-difluorophenyl)
Add 13.0g (40mmol) (R)-the 3-[(tertbutyloxycarbonyl) amido]-1-diazonium-4-(2, the 5-difluorophenyl) butyl-2-ketone is dissolved in the 300ml methyl alcohol, be cooled to-30 ℃ of silver benzoates that add 18.9g (120mmol) diisopropyl ethyl amine and 2.3g (10mmol), reaction solution rises to stirring at room 3h, reaction is finished, remove methyl alcohol under reduced pressure, residuum dissolves with the 200ml methylene dichloride, filtering insoluble solid thing, filtrate concentrates, and the silicagel column purifying obtains solid, this solid is dissolved in the 100ml tetrahydrofuran (THF), add in the water of the 100ml that contains 1.8g (75mmol) lithium hydroxide then, reaction solution stirring at room 16h dilutes with ethyl acetate behind the concentration of reaction solution, saturated sodium bicarbonate and salt washing, use anhydrous magnesium sulfate drying, concentrate 6.6g white solid compound, yield: 52.1%.
Embodiment 67 (R)-N-[3-(tertbutyloxycarbonyl) amido-4-(2, the 5-difluorophenyl) butyryl radicals]-3-trifluoromethyl-5,6,7, the 8-tetrahydrochysene The preparation of-[1,2,4]-triazolo [4,3-a] pyrazine
Under room temperature, throw (R)-3-[(tertbutyloxycarbonyl of 15.8g (50mmol)) amido]-4-(2, the 5-difluorophenyl) butyric acid, 6.8g (50mmol) HOBT (1-hydroxy benzo triazole), DMF100ml, add 20g (75mmol) DCC (dicyclohexylcarbodiimide) then, stirring at room reaction 1h crosses and filters out the solid that reaction generates, and filtrate continuation adds in the reaction flask, add 19.2g (100mmol) 3-trifluoromethyl-5,6,7,8-tetrahydrochysene-[1,2,4]-and triazolo [4,3-a] pyrazine (its preparation method is referring to J.Med.Chem.2005, and 48,141-151), heat up 60 ℃ and stir 3h, reaction is finished, and adds 300ml water, separate out solid, with methyl alcohol and ethyl acetate mixed solution recrystallization, get product 17.6g, yield: 72.1%.
Embodiment 77 (R)-N-[3-(tertbutyloxycarbonyl) amido-4-(4-sulfamic-2,5-difluorophenyl) butyryl radicals]-the 3-trifluoromethyl -5,6,7, the preparation of 8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine
In the exsiccant reaction flask, add methylene dichloride 100ml; 7 (R)-N-[3-(tertbutyloxycarbonyl) amido-4-(2, the 5-difluorophenyl) butyryl radicalies]-3-trifluoromethyl-5,6; 7; 8-tetrahydrochysene-[1,2,4]-triazolo [4; 3-a] pyrazine 14.7g (30mmol); reduce temperature after the stirring and dissolving to-15 ℃, slowly drip the 50ml dichloromethane solution of chloromethane sulphonyl 4.7g (31mmol) under the vigorous stirring, drip and finish; be warming up to 0 ℃ of stirring reaction 6h; reaction is finished, and feeds the exsiccant ammonia under the vigorous stirring, to the pH value be about 9; stop ventilation; stirring reaction 0.5h adds 50ml water respectively; the washing of 50ml saturated sodium-chloride, anhydrous magnesium sulfate drying; remove solvent under reduced pressure; the residuum recrystallizing methanol gets off-white color solid chemical compound 9.8g, yield: 57.6%.
Embodiment 87 (R)-N-[3-amino-4-[4-(N-butylamine formyl radical) sulfamic-2, the 5-difluorophenyl] butyryl radicals]-the 3-fluoroform Base-5,6,7, the preparation of 8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine
In reaction flask, add 7 (R) N-[3-(tertbutyloxycarbonyl) amido-4-(4-sulfamic-2; the 5-difluorophenyl) butyryl radicals]-3-trifluoromethyl-5; 6; 7,8-tetrahydrochysene-[1,2; 4]-triazolo [4; 3-a] pyrazine 22.7g (40mmol), after the dissolving of 200ml methylene dichloride, reduce temperature to 0～5 ℃.Slowly drip n-butyl amine formyl chloride 6.1g (45mmol), elevated temperature to 50 ℃, stirring reaction 5h, be warming up to backflow again, be added dropwise to 40ml5N hydrochloric acid under the vigorous stirring, behind the reaction 1h, reduce to room temperature, tell organic layer, water layer is transferred pH to 9 with sig water under ice bath, separate out solid filtering, water, ethyl acetate washing successively, get crude product, get product 15.5g with ethyl alcohol recrystallization, yield: 68.2%.
Molecular formula: C 21H 26F 5N 7O 4S
Molecular weight: 567.53
Mass spectrum (m/e): 568 (M+1)
Hydrogen spectrum (CDCl 3, 400MHz) δ (ppm): 0.95 (t, 3H), 1.35 (m, 2H), 1.57 (m, 2H), 2.31 (q, 1H), 2.55 (q, 1H), 2.72 (q, 1H), 2.95 (q, 1H), 3.09 (t, 2H), 3.25 (m, 1H), 3.72 (t, 2H), 4.31 (t, 2H), 4.46 (s, 2H), 5.35 (br, 2H), 6.16 (br, 2H), 7.11 (q, 1H), 7.82 (q, 1H).
Ultimate analysis:
Measured value: C, 44.26%; H, 4.89%; F, 16.52%; N, 17.10%; S, 5.83%
Theoretical value: C, 44.44%; H, 4.62%; F, 16.74%; N, 17.28%; S, 5.65%
Embodiment 97 (R)-N-[3-amino-4-[4-[N-(cyclopentyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2, the 5-difluorophenyl] Butyryl radicals]-3-trifluoromethyl-5,6,7, the preparation of 8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine
Preparation method's reference example 8; throw 7 (R)-N-[3-(tertbutyloxycarbonyl) amido-4-(4-sulfamic-2,5-difluorophenyl) butyryl radicalies]-3-trifluoromethyl-5,6; 7; 8-tetrahydrochysene-[1,2,4]-triazolo [4; 3-a] pyrazine 22.7g (40mmol); N-(cyclopentyl is [c] tetramethyleneimine also) amine formyl chloride 8.5g (45mmol) gets product 18.2g, yield: 73.1%.
Molecular formula: C 24H 29F 5N 8O 4S
Molecular weight: 620.6
Mass spectrum (m/e): 621 (M+1)
Hydrogen spectrum (CDCl 3, 400MHz) δ (ppm): 1.37 (m, 2H), 1.48 (m, 1H), 1.55 (m, 1H), 1.59 (m, 2H), 1.66 (m, 2H), 2.34 (q, 1H), 2.56 (q, 1H), 2.64 (dq, 2H), 2.73 (q, 1H), 2.86 (dq, 2H), 2.97 (q, 1H), 3.28 (m, 1H), 3.75 (t, 2H), 4.32 (t, 2H), 4.47 (s, 2H), 5.36 (br, 2H), 5.59 (br, 1H), 6.11 (br, 1H), 7.15 (q, 1H), 7.87 (q, 1H).
Ultimate analysis:
Measured value: C, 46.31%; H, 4.96%; F, 15.16%; N, 17.89%; S, 5.33%
Theoretical value: C, 46.45%; H, 4.71%; F, 15.31%; N, 18.06%; S, 5.17%
Embodiment 10 7 (R)-N-[3-amino-4-[4-[N-(cyclohexyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2,5-two fluorobenzene Base] butyryl radicals]-3-trifluoromethyl-5,6,7, the preparation of 8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine
Preparation method's reference example 8; throw 7 (R)-N-[3-(tertbutyloxycarbonyl) amido-4-(4-sulfamic-2,5-difluorophenyl) butyryl radicalies]-3-trifluoromethyl-5,6; 7; 8-tetrahydrochysene-[1,2,4]-triazolo [4; 3-a] pyrazine 22.7g (40mmol); N-(cyclohexyl is [c] tetramethyleneimine also) amine formyl chloride 9.1g (45mmol) gets product 17.8g, yield: 70.2%.
Molecular formula: C 25H 31F 5N 8O 4S
Molecular weight: 634.62
Mass spectrum (m/e): 625 (M+1)
Hydrogen spectrum (CDCl 3, 400MHz) δ (ppm): 1.31 (m, 2H), 1.46 (m, 2H), 1.50～1.59 (m, 4H), 1.69 (m, 2H), 2.32 (q, 1H), 2.55 (q, 1H), 2.62 (d, 2H), 2.71 (q, 1H), 2.81 (q, 2H), 2.98 (q, 1H), 3.27 (m, 1H), 3.73 (t, 2H), 4.35 (t, 2H), 4.49 (s, 2H), 5.37 (br, 2H), 5.53 (br, 1H), 6.15 (br, 1H), 7.12 (q, 1H), 7.86 (q, 1H).
Ultimate analysis:
Measured value: C, 47.12%; H, 5.08%; F, 14.85%; N, 17.41%; S, 5.19%
Theoretical value: C, 47.31%; H, 4.92%; F, 14.97%; N, 17.66%; S, 5.05%
The preparation of embodiment 11 The compounds of this invention tablets
1, prescription:
Prescription 1
Prescription 2
Figure G200810166086XD00182
Prescription 3
Figure G200810166086XD00183
2, preparation technology: take by weighing raw material and auxiliary material according to prescription, raw material pulverizing is crossed 100 mesh sieves, all the other auxiliary materials are crossed 100 mesh sieves respectively; Raw material, starch, hydroxypropylcellulose and Microcrystalline Cellulose are mixed, add mixer-granulator, add 50% aqueous ethanolic solution of 1%HPMC, stirred 15 minutes, make particle; Particle is dried being lower than under 60 ℃ the condition; Dry good particle adds micropowder silica gel and Magnesium Stearate, and whole grain mixes; Sampling, the work in-process chemical examination; According to the definite sheet weight sheet of chemical examination; Finished product is examined entirely, the packing warehouse-in.

Claims (9)

1. the compound shown in the general formula (I) or its pharmacy acceptable salt:
Figure FSB00000349475900011
Wherein: R 1Represent following groups:
Figure FSB00000349475900012
R 2, R 3Independently represent hydrogen atom or C respectively 1-6Alkyl;
R 4, R 5Independently representative respectively:
(1) hydrogen atom,
(2) halogen atom,
(3) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkyl,
(4) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkoxyl group,
(5) cyano group, or
(6) hydroxyl;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently representative respectively:
(1) hydrogen atom,
(2) cyano group,
(3) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkyl, or
(4) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-6Alkoxyl group.
2. the compound of the claim 1 shown in the general formula (II) or its pharmacy acceptable salt:
Figure FSB00000349475900013
R wherein 1, R 2, R 3, R 4, R 5, X and Y define by claim 1.
3. compound as claimed in claim 2 or its pharmacy acceptable salt:
Wherein: R 1Represent following groups:
Figure FSB00000349475900021
R 2, R 3Independently represent hydrogen atom respectively, methyl or ethyl;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, bromine atoms, methyl, methyl fluoride, difluoromethyl, trifluoromethyl, methoxyl group or cyano group;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently representative respectively:
(1) hydrogen atom, or
(2) straight or branched is replaced or unsubstituted C by 1～5 halogen atom 1-4Alkyl.
4. compound as claimed in claim 3 or its pharmacy acceptable salt:
Wherein: R 1Represent following groups:
Figure FSB00000349475900022
R 2, R 3Independently represent hydrogen atom or methyl respectively;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, methyl, trifluoromethyl or cyano group;
X represents N or C-R 6,
Y represents N or C-R 7,
R wherein 6, R 7Independently represent hydrogen atom, methyl, ethyl or trifluoromethyl respectively.
5. compound as claimed in claim 4 or its pharmacy acceptable salt, wherein said compound is:
7 (R)-N-[3-amino-4-[4-(N-butylamine formyl radical) sulfamic-2, the 5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7,8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine,
7 (R)-N-[3-amino-4-[4-[N-(cyclopentyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2, the 5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7,8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine and
7 (R)-N-[3-amino-4-[4-[N-(cyclohexyl is [c] tetramethyleneimine also) amine formamido-] alkylsulfonyl-2, the 5-difluorophenyl] butyryl radicals]-3-trifluoromethyl-5,6,7,8-tetrahydrochysene-[1,2,4]-triazolo [4,3-a] pyrazine.
6. as the described compound of the arbitrary claim of claim 1～5 or its pharmacy acceptable salt, it is characterized in that described its pharmacy acceptable salt is selected from organic acid salt or inorganic acid salt.
7. as the pharmaceutical composition of the described compound of the arbitrary claim of claim 1～5 or its pharmacy acceptable salt and one or more pharmaceutical carriers and/or thinner, be pharmaceutically acceptable arbitrary formulation.
8. pharmaceutical composition as claimed in claim 7 contains the described compound of the arbitrary claim of claim 1～5 or its pharmacy acceptable salt 10mg～10g as essential activeconstituents.
As the described compound of the arbitrary claim of claim 1～5 or its pharmacy acceptable salt in the application that is used for preparing the medicine that treats and/or prevents non-insulin-dependent diabetes mellitus (NIDDM).
CN200810166086XA 2007-10-24 2008-10-18 Dipeptidase-IV inhibitor sulfonyl urea derivates Active CN101418001B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200810166086XA CN101418001B (en) 2007-10-24 2008-10-18 Dipeptidase-IV inhibitor sulfonyl urea derivates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710113961 2007-10-24
CN200710113961.3 2007-10-24
CN200810166086XA CN101418001B (en) 2007-10-24 2008-10-18 Dipeptidase-IV inhibitor sulfonyl urea derivates

Publications (2)

Publication Number Publication Date
CN101418001A CN101418001A (en) 2009-04-29
CN101418001B true CN101418001B (en) 2011-04-27

Family

ID=40629019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200810166086XA Active CN101418001B (en) 2007-10-24 2008-10-18 Dipeptidase-IV inhibitor sulfonyl urea derivates

Country Status (1)

Country Link
CN (1) CN101418001B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT6064B (en) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinated benzenesulfonamides as inhibitors of carbonic anhydrase

Also Published As

Publication number Publication date
CN101418001A (en) 2009-04-29

Similar Documents

Publication Publication Date Title
JP2021155415A (en) Treatment of type 2 diabetes or obesity or overweight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or pharmaceutical salt thereof
CN103304500B (en) Novel anti-diabetic compound, as well as preparation method and application thereof
CN101357922B (en) New DPP-IV inhibitor
CN103304501B (en) Anti-diabetic compound, as well as preparation method and application thereof
CN101418000B (en) DPP-IV inhibitor derivates containing benzofuran sulfonyl ureas
CN101357921B (en) New dipeptidase-IV inhibitor compound
CN101418001B (en) Dipeptidase-IV inhibitor sulfonyl urea derivates
CN101397300B (en) Dipeptidase-IV inhibitor derivates
CN101357923B (en) Dipeptidase inhibitor compound
CN101417988B (en) Biguanide piperazines dipeptidyl peptidase IV inhibitor
CN101486689B (en) DPP-IV inhibitor with sulfonamide formamide piperazine structure
CN101486688B (en) DPP-IV inhibitor with sulfonyl amine acyl alkyl piperazine structure
CN101357924B (en) Dipeptidase-IV inhibitor compound
CN101417987B (en) DPP-IV inhibitor with sulfonamide formyl piperazine structure
CN101781274B (en) Acylated piperazine dipeptidyl peptidase IV inhibitor
CN102153538B (en) Benzocyclodirivative
CN101723947B (en) Dipeptidase-IV inhibitor compound
CN101781273B (en) Dipeptidylpeptidase IV inhibitor containing guanidyl
CN102234281B (en) Pyrimidine-fused cyclic derivative
CN102276627B (en) Pyridino-heterocycle derivative
CN101550139A (en) Dipeptidase-IV inhibitor containing v-triazolo [b] pyrazine
CN103304504B (en) Anti-diabetic compound, as well as preparation method and application thereof
CN103304503B (en) Anti-diabetic compound, as well as preparation method and application thereof
CN103304502B (en) Anti-diabetic compound, as well as preparation method and application thereof
CN103304499B (en) Anti-diabetic compound, as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BEIJING AOHE PHARMACEUTICAL RESEARCH INSTITUTE CO.

Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD.

Effective date: 20130407

Owner name: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD.

Effective date: 20130407

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 100043 SHIJINGSHAN, BEIJING

TR01 Transfer of patent right

Effective date of registration: 20130407

Address after: 100043, A, block 33, three ancient West Street, Shijingshan District, Beijing

Patentee after: Beijing Aohe Pharmaceutical Research Institute Co., Ltd.

Patentee after: Shandong Xuanzhu Medical Technology Co., Ltd.

Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518

Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd.

DD01 Delivery of document by public notice

Addressee: Huang Xiaoxia

Document name: Notification of Passing Examination on Formalities

TR01 Transfer of patent right

Effective date of registration: 20190619

Address after: Room 301, Building 3, East of Qishanzhuang Village, Zhangjiawan Town, Tongzhou District, Beijing

Patentee after: Beijing Aohe Pharmaceutical Research Institute Co., Ltd.

Address before: 100043 Three Floors, Block A, 33 West Street, Gucheng, Shijingshan District, Beijing

Co-patentee before: Shandong Xuanzhu Medical Technology Co., Ltd.

Patentee before: Beijing Aohe Pharmaceutical Research Institute Co., Ltd.

TR01 Transfer of patent right